Cumberland Pharmaceuticals Inc. — Form 10-Q Summary
Business Context and Reporting Period
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing, and commercializing branded prescription products in hospital acute care, gastroenterology, and oncology supportive care. The filing reports unaudited results for the three and six months ended June 30, 2019, compared with the corresponding 2018 periods.
The company markets eight FDA-approved products, including the recently acquired Vibativ, and is developing ifetroban candidates and a methotrexate product line.
Financial Results and Key Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Net revenue | $11.6 million, up 14% | $23.5 million, up 25% |
| Gross margin | 82.6%, versus 85.0% | 82.9%, versus 83.7% |
| Operating income (loss) | $(0.6) million, versus $(0.9) million | $(0.8) million, versus $(3.3) million |
| Net income (loss) | $(0.6) million, versus $(0.7) million | $(0.6) million, versus $(3.1) million |
| Net loss per diluted share | $(0.04), versus $(0.05) | $(0.04), versus $(0.20) |
| Cash flow from operations | Not separately provided | $1.5 million, versus $1.0 million |
Second-quarter revenue growth was led by Vibativ revenue of $2.6 million, higher Kristalose, Omeclamox-Pak, and Acetadote revenue, and approximately $0.3 million of non-refundable international licensing payments. These gains were partly offset by lower Vaprisol and Ethyol revenue.
For the first six months, Vibativ contributed $4.7 million of revenue. Other revenue included approximately $0.3 million of international upfront payments and $0.8 million of Cumberland Emerging Technologies grant revenue.
Six-month operating expenses increased overall. Selling and marketing expense rose 5% to $10.3 million, general and administrative expense increased to $5.2 million, and amortization increased to $2.1 million primarily because of Vibativ-related intangible assets. Research and development expense declined to $2.7 million from $3.3 million.
At June 30, 2019, cash and cash equivalents were $21.0 million and marketable securities were $9.5 million, for total cash and marketable securities of $30.4 million. Working capital was $29.6 million and the current ratio was 2.3.
The company had $20.0 million outstanding under its revolving credit facility, with an interest rate of 5.15% at June 30, 2019. The facility was extended through July 31, 2021, and the company reported compliance with its tangible capital ratio covenant. The filing states that no borrowing capacity was available at June 30, 2019.
Total assets were $107.5 million and total liabilities were $53.9 million at June 30, 2019. Inventory totaled $26.5 million, including $15.8 million classified as non-current, principally related to Vibativ inventory.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $1.4 million in the second quarter and $4.7 million for the first six months, primarily because Vibativ was not present in the 2018 comparable periods.
- Vaprisol revenue declined by $1.5 million in the second quarter and $1.3 million year to date because of lower sales volumes; 2018 benefited from the arrival of a new product lot after temporary supply issues.
- Ethyol revenue declined by $0.8 million in the second quarter, while Totect revenue declined by $0.4 million for the first six months.
- Product cost as a percentage of revenue increased because of the sales mix, including Vibativ, reducing gross margin.
- Operating and net losses narrowed substantially for the first six months, although the company remained unprofitable.
- Cash declined by $7.0 million during the first six months, primarily from the $5.0 million Vibativ milestone payment, net investment in marketable securities, intangible asset additions, share repurchases, and contingent consideration payments.
- The company repurchased 205,913 common shares for approximately $1.2 million during the first six months and had approximately $8.9 million remaining under its $10 million repurchase authorization at June 30, 2019.
- The company adopted the new lease standard on January 1, 2019, recording a $3.6 million right-of-use asset and $3.8 million of initial lease liabilities. Operating lease liabilities totaled $3.4 million at June 30, 2019.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
Management stated that existing working capital, operating cash flow, and the revolving credit facility were expected to be adequate to finance internal growth, business development initiatives, and capital expenditures for the foreseeable future. The company did not provide quantitative revenue or earnings guidance.
Management’s strategy emphasizes expanding existing brands, acquiring complementary products, advancing the ifetroban pipeline, leveraging commercial infrastructure, expanding international partnerships, and managing expenses to generate positive operating cash flow.
- The FDA established September 2019 as the PDUFA action date for the methotrexate product line. Approval was not assured, and the company had provided additional information in response to FDA requests.
- A full launch of a next-generation Caldolor product was planned for late 2019 following initial shipments in April 2019.
- The company agreed to return U.S. rights to Ethyol and Totect effective September 30, 2019, in exchange for $5.0 million payable over two years. It will no longer market or distribute those products or competing products.
- Vibativ consideration included a $5.0 million milestone payment made in early 2019 and a contingent consideration liability of $9.1 million at June 30, 2019, tied to future net sales royalties of up to 20%.
- The company entered into new international arrangements for Caldolor, Acetadote, and Vibativ, recognizing approximately $0.3 million of upfront payments. Future milestone and royalty amounts remain dependent on regulatory approvals, sales, and other conditions.
- Key risks include dependence on product sales, regulatory approvals, product acquisition and integration, access to capital, inventory obsolescence, pricing and reimbursement pressures, manufacturing and supply continuity, and clinical development outcomes.
- The company had no material legal proceedings reported and stated that there were no material changes to the risk factors in its 2018 Form 10-K.
Important Facts for Investors to Verify
- Whether Vibativ revenue growth and product mix can support improved profitability despite higher amortization, royalties, and selling expenses.
- The timing and outcome of the FDA decision on the methotrexate product line and the commercial launch of the next-generation Caldolor product.
- The financial impact of returning Ethyol and Totect rights, including the timing of the $5.0 million consideration and lost future revenue.
- Remaining borrowing capacity and continued compliance with the revolving credit facility’s financial covenants.
- The recoverability and turnover of the company’s $26.5 million inventory balance, particularly the $15.8 million of non-current inventory associated primarily with Vibativ.
- The valuation and future cash requirements associated with Vibativ’s contingent consideration and royalty obligations.
- Whether operating cash flow remains positive while the company continues share repurchases, clinical development, acquisitions, and international expansion.
- The regulatory, clinical, and commercialization prospects for the ifetroban pipeline and other development candidates.